Vestmark Advisory Solutions’s Dianthus Therapeutics DNTH Stock Holding History

Vestmark Advisory Solutions’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$487K	Buy	+4,997	New	+$436K	﹤0.01%	1152

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vestmark Advisory Solutions's DNTH Position: Q2 2026 in Review

Vestmark Advisory Solutions opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 4,997 shares worth $487K. The stake represents ﹤0.01% of the portfolio and ranks #1152 among its holdings.

268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Vestmark Advisory Solutions held 4,997 shares of Dianthus Therapeutics worth $487K as of Q2 2026.
Dianthus Therapeutics was a new Vestmark Advisory Solutions position in Q2 2026.
Dianthus Therapeutics made up ﹤0.01% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #1152 holding.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.